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Abstract
Background: A hybrid performance measurement system that combines patient-reported outcome data with
administrative data has been developed for South African substance abuse treatment services. This paper describes
the development and psychometric validation of one component of this system, the South African Addiction
Treatment Services Assessment (SAATSA).
Methods: First, a national steering committee identified five domains and corresponding indicators on which
treatment quality should be assessed. A decision was made to develop a patient survey to assess several of these
indicators. A stakeholder work group sourced survey items and generated additional items where appropriate. The
feasibility and face validity of these items were examined during cognitive response testing with 16 patients. This
led to the elimination of several items. Next, we conducted an initial psychometric validation of the SAATSA with
364 patients from residential and outpatient services. Exploratory (EFA) and confirmatory factor analyses (CFA) were
conducted to assess the latent structure of the SAATSA. Findings highlighted areas where the SAATSA required
revision. Following revision, we conducted another psychometric validation with an additional sample of 285
patients. We used EFA and CFA to assess construct validity and we assessed reliability using Cronbach’s measure of
internal consistency.
Results: The final version of the SAATSA comprised 31 items (rated on a four-point response scale) that
correspond to six scales. Four of these scales are patient-reported outcome measures (substance use, quality of
life, social connectedness and HIV risk outcomes) that together assess the perceived effectiveness of treatment.
The remaining two scales assess patients’ perceptions of access to and quality of care. The models for the final
revised scales had good fit and the internal reliability of these scales was good to excellent, with Cronbach’s α
ranging from 0.72 to 0.89.
Conclusion: A lack of adequate measurement tools hampers efforts to improve the quality of substance abuse
treatment. Our preliminary evidence suggests that the SAATSA, a novel patient survey that assesses patients’
perceptions of the outcomes and quality of substance abuse treatment, is a psychometrically robust tool that
can help fill this void.
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Background
This paper describes the developmental process and
measurement properties of a tool designed to assess South
African patients’ perceptions of the quality and outcomes
of substance abuse treatment. The prevalence of substance
use disorders is high in South Africa where an estimated
13 and 6 % of the adult population meet DSM-IV criteria
for a lifetime and past year diagnosis of a substance use
disorder, respectively [1]. Untreated substance use disor-
ders impact negatively on public health in South Africa
through their association with risk for HIV and other in-
fectious diseases [2], non-communicable diseases [3], and
violence and injury [4]. Substance-related risks for HIV
are of particular concern in South Africa where HIV
prevalence is estimated to be 12.2 % among the general
population [5].
Although South Africa has a fairly well-established
substance abuse treatment system, questions have been
raised about the quality and effectiveness of these ser-
vices [6, 7]. Negative perceptions about the quality of
substance abuse treatment are cause for concern as
these perceptions often influence people’s decisions
about whether or not to initiate treatment [6–8].
South Africa is one of many countries where there is
concern about the quality of substance abuse treatment
[9, 11]. In high-income countries, including the United
States (US) [12, 13] and the United Kingdom (UK) [14,
15], these concerns have led to the development of per-
formance measurement systems. These systems rou-
tinely collect data on a standardised set of indicators
that reflect some aspect of treatment quality. When
fully implemented, these systems are valuable as they
generate information that can be used to monitor the
quality of treatment, identify targets for quality im-
provement initiatives, and evaluate activities intended
to improve performance [16, 17].
However, like most other low-and-middle income
countries, South Africa lacks a system for monitoring
the performance of its substance abuse treatment ser-
vices [18, 19]. To fill this void, we set about developing
such a system. During our formative work [19], South
African substance abuse treatment providers reported
willingness to implement a performance measurement
system provided that it comprised brief, psychometric-
ally robust measures that minimised burden for clini-
cians and administrators. Consequently, we developed a
brief survey of patients’ (consumers’) perceptions of the
quality and outcomes of treatment to be used, in con-
junction with process measures constructed from treat-
ment records, to routinely assess service quality.
Although treatment evaluation research has a long
history of collecting objective outcomes data (such as
[15, 20–22]), this is not the case in performance meas-
urement systems routinely implemented in substance
abuse treatment practices [16]. Many treatment pro-
viders are dissuaded from collecting outcomes data due
to the costs associated with objectively assessing out-
comes (either via biological testing or through using
clinician-rated outcome measures) and concerns about
the validity of self-reported substance use outcomes
[16, 23]. As a result, most performance measurement
systems rely on process indicators (such as indicators
of treatment engagement and treatment completion)
contained in administrative databases and treatment re-
cords to measure performance [11–13]. There are many
advantages to using process data to assess quality of
care. These data are relatively easy to collect and can
directly identify specific areas of care that may require
strengthening. There is also accumulating evidence that
certain process indicators predict treatment outcomes
[24–26]. For instance, US national treatment outcome
studies have shown that longer stays in treatment are
associated with better treatment outcomes at one and
five year post-treatment [21, 22]. Despite these benefits,
process indicators generally do not adequately reflect pa-
tients’ perceptions of care or their perceptions of how
treatment affected their functional status and quality of
life. Patient-reported outcome measures (PROMs), even
though subject to the documented limitations of self-
report data such as recall and response bias, can still
reveal how patients experience and are responding to
treatment [27]. In mental health settings, PROMs have
been used to ensure that patients have a voice in treat-
ment planning and service provision and to support the
implementation of patient-centered care [28]. In addition,
PROMs are feasible for under-resourced substance abuse
treatment services to routinely collect as there are signifi-
cantly fewer costs associated with collecting these mea-
sures compared with objective outcomes measures.
Despite these advantages, surveys to assess PROMs are
relatively novel in the substance abuse treatment field.
In our efforts to develop a performance measurement
system for South African substance abuse treatment ser-
vices, we took cognisance of the limitations of perform-
ance measurement systems based only on process data
or reliant only on PROMs. To this end, we developed a
hybrid system that combined patient-reported outcome
data (collected using a patient survey) with process data
from treatment records. In so doing, we wanted to pro-
vide an objective description of the treatment process
while also accounting for patients’ experiences of and
perceived responses to the treatment process. The aim
of this article is to describe the development and meas-
urement properties of one aspect of this system: the
South African Addiction Treatment Services Assessment
(SAATSA). Specific objectives were to: 1) describe the
process of identifying domains and indicators on which
to assess quality and outcomes; 2) describe the process
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of generating survey items for further assessment; 3) es-
tablish the feasibility of using this survey to assess treat-
ment quality and outcomes and the face validity of
survey items; and 4) examine the psychometric proper-
ties (construct validity and reliability) of the survey.
Method
Guided by Streiner and Norman’s [29] framework for
developing measurement scales, this study comprised
five phases implemented from 2008 to 2013. The
study received human subjects approval from the
Centers for Disease Control and Prevention (CDC)
and the University of Stellenbosch’s Health Research
Ethics Committee (N10/03/105). All participants were
asked to provide written informed consent for each
phase of the study.
Phase one: Selection of quality domains and indicators
A national steering committee, comprising key stake-
holders and role players from the substance abuse treat-
ment field, was formed to identify domains on which to
assess treatment. This committee reviewed the domains
used in other mental health and substance abuse per-
formance measurement systems (e.g., [11–13]), and de-
bated the relevance of these domains for South African
services. The steering committee identified five domains
on which treatment should be assessed: effectiveness, ef-
ficiency, access to treatment, person-centred services,
and quality of services. Next, the committee generated a
set of indicators (30 in total) that could be used to meas-
ure each domain. A Delphi consensus panel [30] com-
prising 36 content experts, was used to reduce the
number of indicators. Of these stakeholders, 26 were
substance abuse treatment providers, four were re-
searchers and six were service planners. Each expert was
asked to use a three-point scale (1 = low, 3 = high) to
rate each indicator on how important each was an indi-
cator of substance abuse treatment outcomes or quality
of care, and feasibility of measurement. The research
team calculated the mean importance, mean feasibility
and a combined score for each indicator (using an im-
portance: feasibility mean score ratio of 1:2) and ranked
the indicators in order of their combined scores. The
combined scores were used to reduce the number of in-
dicators: those with a rating of 6.4 or higher (on a scale
of 3 to 9) were retained, reducing the number of indica-
tors to 18. After reducing the number of indicators, the
steering committee decided whether to measure this in-
dicator using a patient survey, data from treatment re-
cords or administrative data typically collected by
treatment programmes. A description of the domains
and corresponding indicators is provided in Table 1.
This exercise revealed the need to develop a survey
measuring patient-reported outcomes and perceptions of
whether care was accessible, person-centred, and of ac-
ceptable quality.
Phase two: Generation, rating and presentation of
SAATSA items
From the steering committee, we developed a work-
group (comprising the research team and representatives
from residential and outpatient treatment facilities) to
generate a list of items to include in the patient survey.
Based on a review of the literature, the survey work-
group identified the 18-item US Substance Abuse
Perceptions of Care Survey [31, 32] as a tool that could
be adapted for use in South Africa [31–33]. Where this
survey did not address our indicators, committee mem-
bers generated additional items. These additional items
related to changes in sexual risk behavior, social con-
nectedness, quality of life, and access to services. After
generating several new items, the SQM steering commit-
tee made decisions about which items would be retained
for the next stage of questionnaire development. This
reduced the original set of 41 items to 33 items. Next,
decisions were made about the instrument’s layout, the
wording of instructions and items, and the response for-
mat. In this version of the SAATSA, all items were rated
on a four point scale, with response options ranging
from “strongly disagree” (1) to “strongly agree” (4). Each
item also had a “not applicable” response option. Finally,
we conducted a lexile analysis and revised the wording
of items until every item was at a Grade 8 reading level.
Phase three: Cognitive response testing
Next, the SAATSA was assessed for feasibility and face
validity during cognitive response testing. Face validity
refers to whether the instrument appears on face value
to measure the key constructs it is purported to measure
[33, 34]. The SAATSA was administered to 16 patients re-
ceiving substance use treatment between March and June
2011. Patients were recruited from two treatment sites
(one residential and one outpatient) in KwaZulu-Natal
(KZN) and two treatment sites (one residential and one
outpatient) in the Western Cape (WC). The WC and
KZN provinces were purposively selected for sampling be-
cause they serve diverse population groups with dissimilar
patterns of drug use and have different types of treatment
infrastructure. These two provinces, collectively, provide a
good representation of the range of service providers and
patients found nationally [19].
During cognitive response testing, patients were
instructed to respond to each item as if they were com-
pleting the survey, and to identify items that were difficult
to read or confusing. The length of time taken to complete
the SAATSA was recorded. Patients were asked a series of
questions about the clarity of the instructions and the
items, what they understood they were being asked,
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suggestions for alternative wording of items, items that
should be added or removed, and the overall format of the
instrument.
Phase four: Psychometric validation of the SAATSA
This phase explored the psychometric properties of the
SAATSA scales (comprised of items developed in the
previous phase) that were hypothesised to correspond to
each of the quality domains. Objectives of this phase
were to determine, by way of validity testing, the extent
to which SAATSA items measured the relevant quality
domains and to modify the SAATSA scales by eliminat-
ing items where necessary and justifiable.
Sample, setting and procedure
We recruited a convenience sample of 364 patients from
three treatment sites (one residential and two out-
patient) in KZN (n = 134) and seven sites (three residen-
tial and four outpatient) in the WC (n = 230) between
September 2011 and July 2012. This sample size is ad-
equate for most factor analyses [35]. Participants were
eligible to participate if they were at least 18 years of
age, had been receiving substance abuse treatment for at
least three weeks, and could read and write English.
Treatment staff were asked to identify patients who met
these inclusion criteria and assess their willingness to
participate. Eligible participants were asked to provide
written informed consent to participate in this pilot test.
Participants were predominantly male (76.1 %), of
Coloured (mixed-race) ancestry (50.0 %) and their ages
ranged from 18 to 74 years. Approximately 40 % of the
sample had not completed high school. The most com-
monly reported primary substances of abuse were alco-
hol (39.8 %), followed by methamphetamine (34.3 %),
heroin (7.1 %), and cannabis (6.5 %). Just over two-thirds
(70.8 %) of the sample were receiving substance abuse
treatment for the first time. Of the participants, 56.6 %
were receiving residential treatment.
Table 1 Summary of domains, indicators and methods of measurement for each indicator
Domain Indicator Mode of measurement
Patient
Survey
Treatment
records
Administrative data from
services
Effectiveness Decreased substance use ✓ ✓
Increased/retained employment or return
to/stay in school
✓
Increased retention in treatment ✓ ✓
Reduced sexual (HIV) risk behaviour ✓ ✓
Improved quality of life ✓
Improved social connectedness ✓
Efficiency Length of delay in obtaining treatment ✓ ✓
Percentage of available treatment slots used ✓
Person-centered
services
Proper assessment of client occurs
(e.g., screening/assessment for mental
illness and HIV/AIDS)
✓
Client participation in the development
and execution of the treatment plan
✓ ✓
Treatment is personalised to fit individual
client’s needs
✓
Client received programme with linguistically
and culturally appropriate content
✓
Access Length of time from request for services to
first service
✓ ✓
Affordability ✓
Equity- access to services is equitable for
different age, race, and gender groups
✓ ✓
Access to HIV testing and counselling and
HIV risk reduction services
✓ ✓
Quality Clients’ are engaged with the treatment
programme
✓
Clients’ perceptions of services received
are positive
✓
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Participants self-completed the SAATSA and a brief
demographic form in a private room at the site. These
forms were placed in a sealed envelope and deposited in
a secure box for safekeeping and collection by the re-
search team.
Data analysis
The validation process used exploratory factor analysis
(EFA) and confirmatory factor analysis (CFA) for validity
testing. Listwise deletion of cases was used to address
missing values, consequently all reported results are for
cases with no missing values. Suitability of items for factor
analysis was determined using two measures; Bartlett’s
Test of Sphericity (significance of p ≤ 0.05) and the
Kaiser-Meyer-Olkin (KMO) measure of sampling ad-
equacy (0.70 and above). The EFA was conducted using
maximum likelihood estimation (MLE) and oblique
minimum rotation to extract and rotate identified fac-
tors [35]. Only factors with an Eigenvalue greater than
1 were selected for consideration [36]. The factor pat-
tern matrix was used to examine loadings of items onto
factors and to assess relevance and applicability of scale
items to the latent construct, thereby directing deci-
sions for item retention and removal.
Following this, CFA was used to confirm the latent struc-
ture observed in the EFA. The adequacy of the latent
models was assessed using three critical fit indices [36]: χ2/
df ratio (a ratio < 4 indicates good fit and < 2 indicates very
good fit); Bentler Comparative Fit Index (CFI), CFI ≥ 0.90
indicates a good fit and CFI ≥ 0.95 indicates very good fit;
and Root Mean Square Error of Approximation (RMSEA),
RMSEA ≤ 0.08 and ≤ 0.05 indicates good fit and very good
fit, respectively [37]. Where applicable, the significance of
improvements in latent models were tested using Chi-
Square tests. All statistical analyses were conducted using
IBM SPSS and AMOS Version 21.0 for Windows [38].
Phase five: Construct validity and reliability testing
Findings from phase four indicated that some of the
SAATSA scales required further development. Conse-
quently, we repeated the steps described in phases two
and three, adding additional items. Phase five involved
administering the revised SAATSA to patients receiving
substance use treatment to establish the construct valid-
ity and internal consistency (reliability) of the SAATSA
subscales.
Sample, setting and procedure
Using the same eligibility and recruitment processes de-
scribed in phase four, 285 participants were recruited from
treatment sites in KZN and the WC provinces between
February 2013 and June 2013. Eligible patients who were
willing to participate were asked to provide written in-
formed consent. Participants then self-completed the
SAATSA in a private room at the treatment facility. This
was linked to a treatment admission form containing
demographic data (but no personal identifiers) through a
unique patient number. Both forms were placed in a
sealed envelope and deposited in a secure box for collec-
tion by the research team.
Similar to the phase four, participants were predomin-
antly male (79.6 %), of Coloured ancestry (56.7 %) and
their ages ranged from 18 to 71 years. Over two-thirds
of the sample (70.7 %) had not completed high school.
The most commonly reported primary substances of
abuse were methamphetamine (38.0 %), followed by al-
cohol (34.5 %), heroin (8.7 %), and cannabis (8.4 %).
Most participants (70.1 %) were receiving substance
abuse treatment for the first time. Of the participants,
53.3 % were receiving residential treatment.
Data analysis
The techniques and analysis parameters discussed in
phase four were applied to examine the latent structure of
the revised scales. In addition, after the scales had been
finalised, scale reliability was assessed using Cronbach’s
measure of internal consistency. A Cronbach’s alpha coef-
ficient of at least 0.70 is considered acceptable, while
≥0.80 is desirable [29]. In all analyses, listwise deletion of
cases was used to address missing values, thus reported
results are limited to cases with no missing values. All
statistical analyses were conducted using IBM SPSS and
AMOS Version 21.0 for Windows [38].
Results
Results of cognitive response testing
Most participants reported that the SAATSA was easy to
complete (94 %) and understand (94 %). All participants
reported that they could complete the SAATSA with very
little assistance. Based on participants’ responses to the
items, several changes were made to the SAATSA: seven
items were discarded and five items were revised and
reworded for clarity or comprehension (see Table 2).
These changes shortened the SAATSA to 26 items. These
26 items were thought to constitute six scales: three
patient-reported outcome measures (PROMs) assessing
treatment effectiveness (specifically changes in substance
use, quality of life and social connectedness), and scales
assessing perceptions of the accessibility, person-
centredness and quality of care.
Initial validation of the SAATSA scales
Results of the initial EFA generally supported the latent
structure of the effectiveness domain. The 12 effective-
ness items loaded onto three factors relating to sub-
stance use, quality of life and social connectedness. To
confirm this latent structure, a CFA was conducted spe-
cifying a one, two and three factor solution. The latter
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Table 2 Changes made to the SAATSA as a result of cognitive response testing
Items for cognitive response testing Changes made to item as a result of testing
1a. The amount of time between when I asked
for and received help was OK.
Discard
1b. The amount of time I had to wait to get
services was acceptable to me.
Retain
2a. It is difficult to pay for my treatment. Discard
2b. I can afford my treatment. Revise: I can afford the treatment I want to receive
3. The staff at this treatment centre are
sensitive to my culture.
Replace: The staff at this treatment centre treat me with respect
4. The staff at this treatment centre are
sensitive to my gender.
Discard
5. The people I went to for treatment services
spent enough time with me.
Revise: The people I went to for treatment services at this centre
spent enough time with me.
6. I help to plan my treatment. Revise: I have a say in deciding about my substance abuse
treatment that I am receiving here
7a. I have received enough information
about the different services.
Discard
7b. The staff at this treatment centre told
me about other services in the community.
Revise: The staff at this treatment centre told me about services
in my area that will help me stay off drugs and alcohol
8a. I have access to all the services I need in
this treatment centre for my recovery
Discard
8b. I am given a choice of services in this
treatment centre.
Retain
9a. This treatment centre teaches me how
to avoid getting HIV.
Retain
9b. This treatment centre helps me reduce my HIV risk. Discard
10. The staff at this treatment centre are
sensitive to my background.
Retain
11. My general health is improving. Retain
12. I am better able to cope when things go wrong. Retain
13. I am better able to accomplish the things I want to do. Retain
14. I am less likely to use alcohol or other drugs. Retain
15. I am doing better at work/finding work or at school. Retain
16. I am more likely to practice safe sex. Retain
17. There is someone who cares about whether I am doing better. Retain
18. I have someone who will help me when I have a problem. Retain
19. I have people in my life who are a positive influence. Retain
20. The people who care about me are supportive
of my treatment.
Retain
21. My friends and family are more able to count on me. Retain
22. I have friends who are not using alcohol or drugs. Retain
23. I have someone who will listen to me when I need to talk. Retain
24a. I think the use of alcohol and drugs is a problem for me. Discard
24b. I now know that using alcohol and drugs is a problem for me. Retain
25. I need to work on my problems with alcohol and/or drugs. Retain
26. The treatment centre is helping me to recover
from using drugs and alcohol.
Retain
27. I would recommend this treatment centre to a friend Retain
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provided the best fit to the data, with all model indices
having acceptable values (χ2/df ratio = 2.21; CFI = 0.98;
RMSEA = 0.06, 90 % CI: 0.04, 0.09).
For items related to substance use, the EFA revealed a
single factor that accounted for 52 % of the common
variance. Three of the five items loaded reasonably well
with one item loading poorly. CFA revealed that a
trimmed four-item subscale provided a better fit for the
data than the original five-item subscale, with all model
indices being excellent (Table 3). For the five items
thought to depict quality of life, a single factor emerged
during EFA that accounted for 62 % of the common
variance. Items 14 and 15 loaded poorly onto this factor.
CFA revealed that a four-item version (excluding item
15) provided a better fit for the data than the original
five-item version. For the seven items thought to reflect
social connectedness, the EFA extracted a single factor
accounting for 61 % of the common variance. Four items
had high factor loadings, with a clear separation between
these and the last three items. A CFA confirmed that a
four-item version provided a better fit than a seven-item
model (Table 3).
The EFA revealed that further developmental work was
required for the access and quality of care domains. There
were only two items referring to access, one of which had
a large amount of missing data. For this reason it was re-
moved from the analysis, rendering the single-item scale
invalid. Similarly, two of the three items initially thought
to belong to the person-centredness domain seemed to re-
flect quality of care; the removal of these items rendered
this scale invalid. Consequently, the one remaining access
item together with the three items on person-centred care
and five items on perceived quality of services were sub-
sumed into a nine-item factor thought to refer to overall
quality of care. The EFA on this scale indicated two factors
that accounted for 53 % of the common variance, suggest-
ing that not all items were working together consistently.
Item 7 was the most problematic. A CFA found that a
nine-item single factor solution provided a poor fit to the
data, with all model indices having unacceptable values
(χ2/df ratio = 5.04; CFI = 0.86; RMSEA = 0.10, 90 % CI:
0.06, 0.16) whereas model indices for an eight-item
solution (excluding item 7) were better (χ2/df ratio = 1.84;
CFI = 0.98; RMSEA = 0.05, 90 % CI: 0.02, 0.09). However,
as some items were still not loading well, we decided to
reformulate these to remove conceptual ambiguities. As
access to treatment is a domain in our quality framework,
we also decided to develop additional items related to ser-
vice access. In addition, we decided to develop another
outcome measure, the HIV risk behaviour subscale, to
better assess changes in HIV risk behaviour as a result of
treatment.
In addition, there were a number of missing responses
largely due to the presence of a “not applicable” response
category for each of the SAATSA items (35 % of cases had
at least one item for which there was a missing response).
To reduce the number of missing responses, we decided
to remove the “not applicable” option from most of the
SAATSA items, except in those instances where it was
conceptually relevant (e.g., items measuring sexual behav-
iour for individuals not engaging in sexual activity). Given
these revisions to the SAATSA items and response cat-
egories, we conducted a further pilot study to assess the
psychometric properties of the revised 39-item SAATSA.
Construct validity and reliability of SAATSA scales
Changes to the SAATSA response categories reduced
the number of missing responses and significantly im-
proved the factor loadings of the SAATSA items. In this
study, less than 15 % of cases had missing responses, as
compared to 35 % in the first pilot study. Findings for
the items reflecting change in substance use generally
confirmed the results of phase four. A single factor
emerged with the item “I have friends who are not using
alcohol or drugs” loading poorly onto the factor
(Table 4). CFA revealed that a four-item version (exclud-
ing this item) provided a much better fit for the data
than a five-item solution. Consequently we discarded
this item. This four-item scale demonstrated good in-
ternal consistency (Cronbach’s α = 0.72).
For the five items relating to quality of life, a single fac-
tor emerged during EFA that accounted for 54 % of the
common variance. The item “I will be more likely to do
better at work or school” still loaded poorly onto this fac-
tor. CFA revealed that a four-item scale excluding this
item provided a better fit to the data than a five-item scale.
We therefore removed this item. This four-item scale
demonstrated excellent internal consistency (Cronbach’s
α = 0.81; Table 4).
Findings for the seven items relating to social connect-
edness also confirmed the results of phase four with a
single factor emerging from the EFA. The item “I have
friends who are not using alcohol or drugs” still loaded
poorly onto the factor (Table 4). A CFA confirmed that a
six-item version of the scale provided a better fit than
the seven-item version; leading to the deletion of this
item. The final scale demonstrated excellent internal
consistency (Cronbach’s α = 0.89).
In this pilot iteration, we developed seven items relat-
ing to HIV. During EFA, all of the items loaded ad-
equately onto a single factor accounting for 43 % of the
common variance. Further inspection of the items sug-
gested the possibility of a two factor solution, with some
items referring to change in HIV risk behaviour and
others to HIV knowledge. CFA revealed that a two factor
model performed better than a single factor approach.
However, as the data still supported the use of the meas-
ure as a single scale we decided to adopt this approach
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Table 3 Results of exploratory factor analyses (EFA) and confirmatory factor analyses (CFA) for the SAATSA substance use, quality of life and social connectedness subscales
SAATSA scales EFA CFA indices
Factor loading χ2/df ratio CFI RMSEA
Substance use scale
13. I am less likely to use alcohol or other drugs 0.39 Five item version = 4.23.
Four item version = 0.97
Five item version = 0.96.
Four item version = 0.99
Five item version = 0.09 (CI: 0.07, 0.18)
Four item version = 0.01 (CI: 0.00, 0.04)
21. I have friends who are not using alcohol
or drugs
0.21
23. I know that using alcohol or drugs is a
problem for me
0.50
24. I need to work on my problems with alcohol
and/or drugs
0.33
25. The treatment centre is helping me recover
from using drugs and alcohol
0.44
Quality of life scale
10. My general health is improving 0.48 Five item version = 3.56.
Four item version = 2.75
Five item version = 0.98.
Four item version = 0.99
Five item version = 0.08 (CI: 0.06, 0.15).
Four item version = 0.07 (CI: 0.02, 0.10)
11. I am better able to cope when things
go wrong
0.45
12. I am better able to accomplish the things
I want to do
0.56
14. I expect to do better at work/finding work
or at school
0.41
15. I am more likely to practice safe sex 0.32
Social connectedness scale
16. There is someone who cares about whether
I am doing better
0.61 Seven item version = 2.86.
Four item version = 2.25.
Seven item version = 0.98.
Four item version = 0.99.
Seven item version = 0.07 (CI: 0.01, 0.12).
Four item version = 0.06 (CI: 0.02, 0.09).
17. I have someone who will help me when
I have a problem
0.66
18. I have people in my life who are a
positive influence
0.64
19. The people who care about me are supportive
of my treatment
0.68
20. My friends and family are more able to
count on me
0.51
21. I have friends who are not using alcohol
or drugs
0.26
22. I have someone who will listen to me
when I need to talk
0.49
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Table 4 Construct validity and reliability of the revised SAATSA subscales
SAATSA scales EFA CFA indices Internal consistency
Factor
loading
χ2/df ratio CFI RMSEA Cronbach’s α
Substance use scale
17. I am less likely to use alcohol or other
drugs
0.44 Five item version = 1.82.
Four item version = 0.59
Five item version = 0.99.
Four item version = 0.99
Five item version = 0.05 (CI: 0.00, 0.10)
Four item version = 0.01 (CI: 0.00, 0.07)
Cronbach’s α
(4 item scale) = 0.72
25. I have friends who are not using alcohol
or drugs
0.30
27. I know that using alcohol or drugs is a
problem for me
0.83
28. I need to work on my problems with
alcohol and/or drugs
0.62
29. The treatment centre is helping me to
recover from using drugs and alcohol
0.74
Quality of life scale
14. My general health is improving 0.66 Five item version = 5.18.
Four item version = 3.52
Five item version = 0.92. Four item version
= 0.99
Five item version = 0.11 (CI: 0.07, 0.19).
Four item version = 0.08 (CI: 0.04, 0.15).
Cronbach’s α
(4 item scale) = 0.81
15. I am better able to cope when things
go wrong
0.77
16. I am better able to accomplish the
things I want to do
0.72
18. In the future I will be more likely to
do better at work or at school
0.40
19. I am more likely to practice safe sex 0.59
Social connectedness scale
20. There is someone who cares about
whether I am doing better
0.79 Seven item version = 1.84.
Six item version = 1.61
Seven item version = 0.98.
Six item version = 0.99
Seven item version = 0.06. (CI: 0.02, 0.12).
Six item version = 0.05 (CI: 0.00, 0.09).
Cronbach’s α
(6 item scale) = 0.89
21. I have someone who will help me
when I have a problem
0.84
22. I have people in my life who are a
positive influence
0.76
23. The people who care about me are
supportive of my treatment
0.74
24. My friends and family are more able
to count on me
0.60
25. I have friends who are not using
alcohol or drugs
0.36
26. I have someone who will listen to
me when I need to talk
0.65
HIV risk scale
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Table 4 Construct validity and reliability of the revised SAATSA subscales (Continued)
33. I am more likely to use condoms when
I have sex.
0.69 Single scale = 3.27 Single scale = 0.94 Single scale = 0.07 (CI: 0.03, 0.12). Cronbach’s α = 0.81
34. I am less likely to use alcohol and drugs
before I have sex.
0.45 Two scales =1.68 Two scales =0.98 Two scales =0.04 (CI: 0.01, 0.09).
35. I am more likely to only have sex with
one partner.
0.32
36. I am more likely to use condoms properly. 0.71
37. I know it’s important to know my HIV status. 0.74
38. I know where I can get tested for HIV. 0.77
39. I know where I can get treatment for HIV. 0.78
Quality scale
8. The staff at this treatment centre treat me
with respect.
0.56 Seven item version = 1.51.
Six item version = 0.39
Seven item version = 0.98.
Six item version = 0.99
Seven item version = 0.04. (CI: 0.00, 0.08).
Six item version = 0.02 (CI: 0.00, 0.05).
Cronbach’s α
(6 item scale) = 0.74
9. The people I went to for treatment services
spent enough time with me.
0.56
10. I have a say in deciding about my substance
abuse treatment that I am receiving here
0.56
11. The staff told me about services that will
help me staff off alcohol and drugs.
0.46
12. This treatment centre teaches me how
to avoid getting HIV.
0.61
13. The staff at this treatment centre are
sensitive to my background
0.57
30. I would recommend this treatment
centre to a friend
0.62
Access scale
1. The amount of time I had to wait
to get services was acceptable to me.
0.67 Six item version = 3.35.
Five item version = 1.60
Six item version = 0.95.
Five item version = 0.99
Six item version = 0.09. (CI: 0.06, 0.13).
Five item version = 0.05 (CI: 0.00, 0.10).
Cronbach’s α
(5 item scale) = 0.76
3. The location of this treatment centre
is convenient for me.
0.66
4. I feel safe travelling to this treatment centre. 0.69
5. It is easy for me to obtain the treatments
offered by this centre.
0.71
6. My family is able to access services
provided by this treatment centre.
0.59
7. I can afford the transport costs of getting
to this treatment centre
0.63
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with the understanding that future applications could
elect to apply the scale as a single or two factor solution.
The internal consistency of this scale was excellent
(Cronbach’s α = 0.81).
We had also expanded the access items from two to
seven items. However, we excluded item 2, “I can afford
the treatment I want to receive”, from the SAATSA as
more than 40 % of the sample indicated that this was
not applicable to them as they were receiving free ser-
vices. For the six remaining items, a single factor
emerged during EFA that accounted for more than 40 %
of the common variance. Only one item referring to ac-
cess by family members loaded poorly onto the factor
(Table 4). CFA revealed that a five-item model (exclud-
ing this item) provided a better fit to the data than a six-
item version. This item was removed from the SAATSA.
The final five-item scale demonstrated good internal
consistency (Cronbach’s α = 0.76).
For items related to perceived quality of services, EFA
suggested a two factor solution that accounted for 42 %
of the common variance. Only two items loaded onto
the second factor: one loaded more strongly onto the
first factor and the second (“The treatment centre tea-
ches me how to avoid getting HIV”) loaded almost
equally on both factors. A CFA was conducted to test
whether or not removing this item from the subscale
would result in better performance. Results from the
CFA indicate that a six-item model excluding this item
provided a better fit to the data than a seven-item solu-
tion (Table 4). We removed this item from the SAATSA.
The final six-item scale demonstrated good internal
consistency (Cronbach’s α = 0.76).
Overall, the results of the CFA led to the reduction of
the SAATSA from 39 to 31 items (see Table 5 for final
list of items). This reduction was desirable for scientific
parsimony and because of the limited time available in
treatment services for patient assessments.
Discussion
A lack of adequate measurement tools hampers efforts to
improve the quality of substance abuse treatment. To help
fill this void, we describe the development and measure-
ment properties of a novel instrument, the SAATSA. To
the best of our knowledge, this is the first tool designed to
routinely assess patients’ perceptions of the outcomes and
quality of substance abuse treatment. Although national
treatment evaluation studies conducted in the US and
elsewhere have collected both process and outcomes data,
these data have been collected as part of large, often once-
off research initiatives in which patients were tracked dur-
ing and post-treatment (see for example [20–22, 39–41]).
The SQM initiative differs from traditional treatment
evaluation research in that it is a pragmatic performance
measurement system designed to be continuously
implemented by treatment providers (rather than re-
searchers) for the purposes of routinely monitoring the
quality of the services that they provide. Through a par-
ticipatory and consensus-driven process, treatment stake-
holders identified a set of domains and corresponding
indicators for assessing substance abuse treatment quality.
Next we created questionnaire items to measure indica-
tors for these domains. The face validity of the question-
naire was established through review by experts, and
through cognitive response testing with service users. The
construct validity and initial reliability of the SAATSA was
established during two rounds of pilot-testing with service
users.
The rigorous manner in which the SAATSA was de-
veloped not only ensured a parsimonious representation
of the underlying quality framework (by highlighting
several items that could be eliminated), but also pointed
to ways in which the SAATSA’s representation of the
underlying quality of care framework could be improved.
More specifically, we expected that factors identified
during EFA would be related to four of the domains in
our quality framework. We found support for our
hypothesised effectiveness domain, with initial EFA and
CFA demonstrating that this domain comprised three
dimensions that corresponded to substance use, social
connectedness and quality of life. However, these initial
analyses did not provide support for separate domains
pertaining to access to care, person-centred services and
quality of care. We used these findings to guide the de-
velopment of additional survey items relating to access
to treatment as well as HIV risk behaviour.
With these revisions, the construct validity of the
SAATSA improved, revealing better correspondence
with our quality framework. More specifically, this next
phase of EFA and CFA revealed four unique dimensions
relating to the effectiveness domain: substance use, qual-
ity of life, social connectedness, and HIV risk. In
addition, two dimensions were identified that relate to
perceptions of access to treatment and quality of care.
Additional analysis provided strong support for the reli-
ability of these SAATSA scales. Taken together, these
findings provide preliminary evidence that the SAATSA
is a psychometrically sound measure of patient-reported
quality and outcomes of substance abuse treatment.
The SAATSA can be grouped together with other
types of measures described in the health services qual-
ity literature, in particular patient-reported outcome
measures (PROMs) and tools for assessing perceptions
of care. PROMs have been adopted as quality improve-
ment tools in the UK [42], US [42, 43], Australia [44, 45]
and Sweden [43]; although their use within substance
abuse treatment services is limited. While some sub-
stance abuse services do use standardised tools to assess
patient outcomes, these tools are clinician-administered
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(such as the Addiction Severity Index or Texas Christian
University short forms [46]), and are either lengthy and
time-consuming to use or they assess substance abuse
symptom alleviation only. The SAATSA is distinct from
these measures as it is a brief, self-administered tool that
is able to assess substance abuse symptom reduction as
well as patients’ perceptions of how treatment impacted
on their quality of life and social connectedness- factors
that are known to be important predictors of recovery
[47]. In addition, unlike other standardised tools for
measuring change in substance use, items contained in
the SAATSA are anchored to the most recent treatment
episode, making it suitable to use for managing perform-
ance of treatment services.
The SAATSA can also be grouped together with tools
that assess perceptions of care and satisfaction with ser-
vices such as Texas Christian University’s treatment sat-
isfaction questionnaire [46]. However, the SAATSA is
novel in that it examines patient-reported outcomes and
perceptions of care in a single measure. Another
strength of this tool is its brevity. On average, the
SAATSA took less than 10 min to complete. Having one
Table 5 Final SAATSA scales and items
SAATSA scales Scale items
Quality domain
Access Item 1. The amount of time I had to wait to get services was acceptable to me.
Item 3. The location of this treatment centre is convenient for me.
Item 4. I feel safe travelling to this treatment centre.
Item 5. It is easy for me to obtain the treatments offered by this centre.
Item 7. I can afford the transport costs of getting to this treatment centre
Quality Item 8. The staff at this treatment centre treat me with respect.
Item 9. The people I went to for treatment services spent enough time with me.
Item 10. I have a say in deciding about substance abuse treatment I am receiving here.
Item 11. The staff told me about services that will help me stay off drugs and alcohol.
Item 13. The staff at this treatment centre are sensitive to my background.
Item 30. I would recommend this treatment centre to a friend.
Effectiveness domain
Quality of life Item 14. My general health is improving.
Item 15. I am better able to cope when things go wrong.
Item 16. I am better able to accomplish the things I want to do.
Item 19. I am more likely to practice safe sex.
Social connectedness Item 20. There is someone who cares about whether I am doing better.
Item 21. I have someone who will help me when I have a problem.
Item 22. I have people in my life who are a positive influence.
Item 23. The people who care about me are supportive of my treatment.
Item 24. My friends and family are able to count on me more
Item 26. I have someone who will listen to me when I need to talk.
Substance abuse Item 17. I am less likely to use alcohol or other drugs.
Item 27. I now know that using alcohol and drugs is a problem for me.
Item 28. I need to work on my problems with alcohol and/or drugs.
Item 29. The treatment centre is helping me to recover from using drugs and alcohol.
HIV Item 33. I am more likely to use condoms when I have sex
Item 34. I am less likely to use alcohol and drugs before I have sex
Item 36. I am more likely to only have sex with one partner
Item 37. I am more likely to use condoms properly
Item 38. I know it is important to know my HIV status
Item 39. I know where I can get tested for HIV
Item 40. I know where I can get treatment for HIV
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patient-administered tool that serves multiple functions
and that poses little administrative burden for clinicians
is likely to improve the chances of this tool being utilised
in busy and under-resourced treatment settings [19].
While our focus has been on the development of a tool
to assess the quality of South African substance abuse
treatment services, we believe that the SAATSA can be
applied more broadly. It was designed to be easily adapt-
able and can be modified to assess the quality of other
levels of substance abuse intervention, although additional
items specific to these services may need to be added to
the tool. Second, items contained in the questionnaire are
likely to be of relevance to treatment services in other
similar low-and-middle income countries. However, the
HIV risk scale may not be relevant in countries where
HIV is not a significant health problem and in these coun-
tries, its use can be omitted.
The SAATSA was tested in a variety of treatment set-
tings (outpatient/ambulatory, inpatient, residential), types
and durations of treatment programmes. Although not re-
ported here, we found no differences in the reliability of
the subscales across different types of services. This im-
proves confidence in its utility for the mix of treatment
services available in other countries. However, more re-
search is needed to understand the strengths and limita-
tions of the questionnaire when it is used for other levels
of substance abuse intervention and in other countries.
These findings should be considered in the light of
some study limitations. First, we did not include former
patients in the national steering committee, primarily
because until very recently, substance abuse treatment
service users in South Africa were not well organised
into consumer interest groups. We acknowledge that
treatment service users may have had different views of
quality, however we believe we have mitigated this limi-
tation through conducting considerable outreach to pa-
tients during the developmental phases of the SAATSA.
In these phases, we were able to capture patients’ per-
ceptions and understanding of treatment quality. Since
these early developmental phases, the steering commit-
tee has been expanded to include former patients. Sec-
ond, our sample was limited to patients who spoke
English well and were at least 18 years of age. Although
the SAATSA has since been translated into several other
South African languages, further research is needed to
establish the psychometric properties of these other lan-
guage versions. Related to this, it is possible that some
of the SAATSA items are not suitable for use with ado-
lescent populations. We plan to use a similar process to
develop an adolescent version of the SAATSA. Third,
the methods used to validate the SAATSA were limited
to factor analyses, although CFA was performed using
robust analytic techniques. Additional testing is required
to establish the predictive and convergent validity of the
SAATSA scales. Related to this, the SAATSA is a self-
report measure of patient outcomes and is subject to all
of the well-documented limitations of self-report mea-
sures. Future research should consider comparing the
performance of the SAATSA substance use scale against
objective measures of drug use. Future research should
also investigate the discriminant validity of the SAATSA
scales – their ability to differentiate different treatment
outcomes as well as subsamples of respondents. Further,
the current examination of scale reliability was confined
to tests of internal consistency, and it remains for future
work to investigate the test-retest reliability of the
SAATSA. Additionally, we did not have a sufficient sam-
ple size in either of these pilot studies to confirm our
final model with a hold-out sample or to test for item
invariance across multiple subgroups. Nevertheless, the
fact that we found very similar findings for our analyses
in two separate pilot tests is encouraging and suggestive
of the stability of the SAATSA’s underlying factor
structure.
Conclusions
We have provided preliminary evidence supporting the
construct validity and internal consistency of the
SAATSA, suggesting that it is an appropriate tool for
assessing the quality of substance abuse treatment.
There are several ways in which this tool can be used.
First, it can be used to identify themes around quality of
care at specific practice settings that require further in-
depth examination using qualitative approaches. Second,
the SAATSA can be used as part of a participatory ap-
proach for identifying areas where programmes can be
strengthened. In such an approach [48], providers are
asked to provide inputs on their treatment setting which
are used to understand the data generated from the
SAATSA so that useful and practice-specific strategies
for improving treatment quality can be developed. Third,
it can be used as a monitoring tool to assess the impact
of interventions to improve quality and outcomes of
treatment. While findings suggest that the SAATSA is a
psychometrically robust measure of patient-reported
outcomes, it is only one component of a performance
measurement system that seeks to combine patient-
reported outcome data with administrative data. A
remaining challenge is how to integrate these patient-
reported outcomes with administrative data to ensure
that this hybrid performance measurement model func-
tions effectively. Ensuring this system functions properly
is essential as the valid measurement of treatment qual-
ity could lead to improvements in treatment services,
and ultimately better treatment outcomes.
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